NEUROPROTECTIVE EFFECT OF MORIN HYDRATE AND PARKINSONS DISEASE AGAINST PARKINSONS DISEASE

Abstract

Parkinson's disease is among the most prevalent neurodegenerative disease worldwide. The aim of the research was to assess the neuroprotective effect of a combination of Gemigliptin and Morin hydrate in reserpine-induced parkinsonism. Orofacial dyskinesia was induced by using reserpine (1 mg/kg, s.c.). For three days on alternate days, rats receiving reserpine injections showed a significant increase in their tongue protrusions (TP) and vacuous chewing movements (VCM), as well as a decrease in their locomotor activity. Gemigliptin (50 and 100 mg/kg, p.o. for 5 days) and Morin hydrate (50 and 100 mg/kg, p.o. for 5 days) treatments both shown dose-dependent, significant reductions in VCM and TP. Significant increases in locomotor activity were also demonstrated with gemigliptin and morin hydrate. Reserpine significantly enhanced lipid peroxidation and decreased levels of antioxidant enzymes that are meant to defend against damage, such as catalase (CAT), reduced glutathione (GSH), and superoxide dismutase (SOD) in rat brain. These effects of reserpine on oxidative stress markers were reversed by the combination of morin hydrate and gemigliptin, suggesting amelioration of oxidative stress in rat brains. The results of this study indicate that gemigliptin and morin hydrate together provide protection against reserpine- induced orofacial dyskinesia. Therefore, these medications may offer a strategic therapeutic option for the treatment of parkinsonism.